A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Identifieur interne : 000864 ( Main/Exploration ); précédent : 000863; suivant : 000865A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Auteurs : C Olanow [États-Unis] ; Olivier Rascol ; Robert Hauser ; Paul. Feigin ; Joseph Jankovic [États-Unis] ; Anthony Lang ; William Langston ; Eldad Melamed ; Werner Poewe ; Fabrizio Stocchi ; Eduardo TolosaSource :
- The New England journal of medicine ; 2009.
English descriptors
- KwdEn :
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Indans (administration & dosage), Indans (adverse effects), Male, Middle Aged, Monoamine Oxidase Inhibitors (administration & dosage), Monoamine Oxidase Inhibitors (adverse effects), Neuroprotective Agents (administration & dosage), Neuroprotective Agents (adverse effects), Parkinson Disease (classification), Parkinson Disease (drug therapy), Research Design, Severity of Illness Index.
- MESH :
- chemical , administration & dosage : Indans, Monoamine Oxidase Inhibitors, Neuroprotective Agents.
- chemical , adverse effects : Indans, Monoamine Oxidase Inhibitors, Neuroprotective Agents.
- classification : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Research Design, Severity of Illness Index.
Abstract
A therapy that slows disease progression is the major unmet need in Parkinson's disease.
DOI: 10.1056/NEJMoa0809335
PubMed: 19776408
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000106
- to stream PubMed, to step Curation: 000106
- to stream PubMed, to step Checkpoint: 000128
- to stream Ncbi, to step Merge: 000259
- to stream Ncbi, to step Curation: 000259
- to stream Ncbi, to step Checkpoint: 000259
- to stream Main, to step Merge: 000875
- to stream Main, to step Curation: 000864
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A double-blind, delayed-start trial of rasagiline in Parkinson's disease.</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C" last="Olanow">C Olanow</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA. warren.olanow@mssm.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author><author><name sortKey="Hauser, Robert" sort="Hauser, Robert" uniqKey="Hauser R" first="Robert" last="Hauser">Robert Hauser</name></author><author><name sortKey="Feigin, Paul D" sort="Feigin, Paul D" uniqKey="Feigin P" first="Paul" last="Feigin">Paul. Feigin</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name></author><author><name sortKey="Langston, William" sort="Langston, William" uniqKey="Langston W" first="William" last="Langston">William Langston</name></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1056/NEJMoa0809335</idno><idno type="RBID">pubmed:19776408</idno><idno type="pmid">19776408</idno><idno type="wicri:Area/PubMed/Corpus">000106</idno><idno type="wicri:Area/PubMed/Curation">000106</idno><idno type="wicri:Area/PubMed/Checkpoint">000128</idno><idno type="wicri:Area/Ncbi/Merge">000259</idno><idno type="wicri:Area/Ncbi/Curation">000259</idno><idno type="wicri:Area/Ncbi/Checkpoint">000259</idno><idno type="wicri:Area/Main/Merge">000875</idno><idno type="wicri:Area/Main/Curation">000864</idno><idno type="wicri:Area/Main/Exploration">000864</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A double-blind, delayed-start trial of rasagiline in Parkinson's disease.</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C" last="Olanow">C Olanow</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA. warren.olanow@mssm.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author><author><name sortKey="Hauser, Robert" sort="Hauser, Robert" uniqKey="Hauser R" first="Robert" last="Hauser">Robert Hauser</name></author><author><name sortKey="Feigin, Paul D" sort="Feigin, Paul D" uniqKey="Feigin P" first="Paul" last="Feigin">Paul. Feigin</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name></author><author><name sortKey="Langston, William" sort="Langston, William" uniqKey="Langston W" first="William" last="Langston">William Langston</name></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name></author></analytic><series><title level="j">The New England journal of medicine</title><idno type="e-ISSN">1533-4406</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Indans (administration & dosage)</term><term>Indans (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Monoamine Oxidase Inhibitors (administration & dosage)</term><term>Monoamine Oxidase Inhibitors (adverse effects)</term><term>Neuroprotective Agents (administration & dosage)</term><term>Neuroprotective Agents (adverse effects)</term><term>Parkinson Disease (classification)</term><term>Parkinson Disease (drug therapy)</term><term>Research Design</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Indans</term><term>Monoamine Oxidase Inhibitors</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Indans</term><term>Monoamine Oxidase Inhibitors</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Research Design</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A therapy that slows disease progression is the major unmet need in Parkinson's disease.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li><li>État de New York</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><noCountry><name sortKey="Feigin, Paul D" sort="Feigin, Paul D" uniqKey="Feigin P" first="Paul" last="Feigin">Paul. Feigin</name><name sortKey="Hauser, Robert" sort="Hauser, Robert" uniqKey="Hauser R" first="Robert" last="Hauser">Robert Hauser</name><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name><name sortKey="Langston, William" sort="Langston, William" uniqKey="Langston W" first="William" last="Langston">William Langston</name><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C" last="Olanow">C Olanow</name></region><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000864 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000864 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19776408
|texte= A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19776408" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |